Building on the inaugural 2007 conference, CBI’s 2nd Annual Oncology Clinical Trial Summit focuses on the complexity of oncology clinical trials which require a different approach than trials in other therapeutic areas. Determining appropriate trial designs, effectively recruiting and enrolling patients, determining biomarkers and choosing the most effective endpoints all contribute to the complexity of managing oncology trials.
The regulatory landscape in oncology is changing and it is critical to understand the impact that these changes will have on cancer trials. At the 2nd Annual Summit, expect to hear expert analysis and insight on the latest trial development and regulatory strategies and determining appropriate biomarkers and endpoints for optimum trial results.
Hear Expert Analysis and Insight on:
The current metrics for the time, cost and success rates for cancer therapeutics compared to other therapeutic areas
Strategies establishing viable relationships with the Oncology Review Divisions to facilitate product development
Tools to determine the utility and feasibility of biomarkers in preclinical models
NCI efforts to create resources to address imaging standards for drug response
Ways to ensure the integrity of the Progression Free Survival endpoint